Aksìa is considering the sale of Coc Farmaceutici

Given the exploratory mandate to Houlihan Lokey

The future of Coc Farmaceutici is being examined by the shareholder Aksìa Group. According to Carlo Festa in the Sole 24 Ore, the private equity firm is studying the valorisation of the subsidiary and has entrusted an exploratory mandate to Houlihan Lokey.

The process will start in the coming weeks and the dossier would have attracted several private equity funds and multinationals in the sector. Coc Farmaceutici was founded in 1985 and is active in the contract manufacturing of pharmaceutical products for the ophthalmic market. In recent years it has grown significantly, above all thanks to the acquisition of Tubilux Pharma, another company in the sector, which took place two years ago.

From the industrial and commercial integration of the two, a group was born with a 2021 turnover of more than 70 million euros (and which should exceed 80 million in 2022). The consolidation has made it possible to: develop the presence in Italy and abroad and seize the opportunities for international growth, reports the business daily. Aksìa Goup took over Coc Farmaceutici through Aksia Capital IV in 2016, when it was part of the Lameplast Coc group. Lameplast was sold to Tekniplex in 2019, but Coc Farmaceutici remained in the portfolio.